Navigation Links
SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS
Date:2/12/2009

laborators' ability, to successfully satisfy all pertinent regulatory requirements and continue to commercialize products incorporating Senomyx's flavor ingredients in foods and beverages; the continued funding of Senomyx discovery and development programs by its collaborators; Senomyx's ability to strengthen discovery and development capabilities; our ability to secure necessary or desirable intellectual property rights; and whether any published scientific discoveries of Senomyx contribute to commercial products or Senomyx's ability to generate revenues. Risks that contribute to the uncertain nature of the forward-looking statements include: Senomyx is dependent on its product discovery and development collaborators for all of Senomyx's revenue; Senomyx is dependent on its current and any future product discovery and development collaborators to develop and commercialize any flavor ingredients Senomyx may discover; Senomyx may be unable to develop flavor ingredients useful for formulation into products; development activities for new flavor ingredients may not demonstrate an acceptable safety profile; Senomyx or its collaborators may be unable to obtain and maintain the regulatory approval required for flavor ingredients to be incorporated into products that are sold; even if Senomyx or its collaborators receive a regulatory approval and incorporate Senomyx flavor ingredients into products, those products may never be commercially successful; Senomyx flavor ingredients may not be useful or cost-effective for formulation into products; and Senomyx's ability to compete in the flavor ingredients market may decline if Senomyx does not adequately protect its proprietary technologies. These and other risks and uncertainties are described more fully in Senomyx's most recently filed SEC documents, including its Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q, under the headings "Risks Related to Our Business" and "Risks Related to Our Industry
'/>"/>
SOURCE Senomyx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW BITTER BLOCKERS
2. SENOMYX, INC. fourth quarter AND FISCAL YEAR-END 2008 Earnings conference call scheduled for February 12, 2009
3. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE 11TH ANNUAL NEEDHAM GROWTH STOCK CONFERENCE
4. SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE
5. SENOMYX ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS
6. SENOMYX ANNOUNCES RECEIPT OF MILESTONE PAYMENT FROM THE COCA-COLA COMPANY
7. SENOMYX, INC. THIRD QUARTER 2008 EARNINGS CONFERENCE CALL SCHEDULED FOR NOVEMBER 6, 2008
8. SENOMYX CO-FOUNDER AND SCIENTIFIC ADVISORY BOARD MEMBER ROGER TSIEN, PH.D., AWARDED NOBEL PRIZE IN CHEMISTRY
9. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE WACHOVIA CONSUMER GROWTH CONFERENCE
10. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CANACCORD ADAMS 28TH ANNUAL GLOBAL GROWTH CONFERENCE
11. SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW SUCROSE ENHANCER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , June 1, 2015  Turing Pharmaceuticals AG announced ... Oreste Salinas , MD, MSc,  has joined the ... Dr. Salinas, who holds a medical degree ... a record of significant accomplishments in the pharmaceutical ... Dr. Salinas has played a leadership role ...
(Date:6/1/2015)... Korea , June 1, 2015 This ... (GCBT) kicked off construction today on its biopharmaceutical facility ... Campus. The CA$315 million project represents one of the ... in the biopharmaceutical industry, giving place to ... albumin manufacturing plant in Canada . ...
(Date:6/1/2015)... June 1, 2015 GenomeDx Biosciences ... analysis platform, successfully classified various subtypes of ... of certain biomarkers, including one type associated ... unique genomic signature has potential as a ... chemotherapy in patients with muscle-invasive bladder cancers ...
(Date:6/1/2015)... , June 1, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... March 31, 2015.  Biorem,s complete 2015 first quarter financial statements and ... Financial Summary:Three-months ended March 31,(in CDN$,000 except per share ... 4,689 , 1,974 Gross profit , 1,531 ... Net earnings (loss) , 528 , (531) Basic ...
Breaking Biology Technology:Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3Green Cross Biotherapeutics Kicks Off Construction in Montreal 2Green Cross Biotherapeutics Kicks Off Construction in Montreal 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4Biorem Reports Increased Revenues and Earnings for First Quarter 2Biorem Reports Increased Revenues and Earnings for First Quarter 3
... May 12 Aton Pharma, Inc., a global,specialty ... a,distribution agreement with Meizler Biopharma S/A to commercialize,CUPRIMINE(R) ... in,Brazil, and Meizler is working to obtain regulatory ... medically essential products, and Aton is,committed to making ...
... Poised to Impact Lung Cancer Care, ST. ... medical,device start-up company, has secured $4.75M in venture ... IG4 delivery system for minimally,invasive biopsy and ablation ... and was joined by Advantage Capital Partners and ...
... (NYSE:,CVD) today announced that it will present at the ... 2008 at 10:30 am ET. Investors may,access a live ... order to,register and download any necessary software, please log ... New Jersey, is one of the,world,s largest and most ...
Cached Biology Technology:Aton Pharma Announces Distribution Partnership in Brazil 2Veran Medical Technologies Secures $4.75M in First Institutional Funding 2
(Date:5/11/2015)... , May 11, 2015  Through a well-rounded UAS ... had a strong showing at AUVSI,s Unmanned 2015 ... representatives of Ohio,s UAS industry met ... abroad from all points along the UAS ecosystem. ... Coalition,s (DDC) Vice President for Aerospace Rich Knoll . ...
(Date:5/6/2015)... 6, 2015 LifeBEAM, a developer of bio-sensing ... announced today that they will expand their partnership in ... bio-sensing cycling helmet and the first joint project between ... colors in order to give cyclists more style choices ... LifeBEAM and Lazer announced their plan to release a ...
(Date:4/21/2015)... 2015 High crime rate, ... boosting access control systems market in Saudi ... recently published report by TechSci Research " Saudi Arabia Access ... control systems market in Saudi Arabia ... access control systems market in the Kingdom is growing ...
Breaking Biology News(10 mins):Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3
... patients was given potentially hazardous medication during 2007. That ... and her co-authors in the current issue of the ... 2012; 109[5]: 69-75). Giving certain medical drug ... drug effects, and for this reason experts describe them ...
... women with a previous history of cardiovascular pathologies seem ... of supplementation. The research is published in detail in ... some studies have suggested that supplementation with B vitamins ... randomised clinical trials conducted internationally in recent years remain ...
... senior scientist and director of the Marine Biological Laboratory ... Antarctic Program Blue Ribbon Panel. The 12-member panel, ... the White House Office of Science and Technology Policy ... is tasked with examining the status and capabilities of ...
Cached Biology News:Vitamin B and omega-3 supplementation and cancer: New data 2MBL's Hugh Ducklow appointed to Antarctic Blue Ribbon Panel 2
... The Caliper Sciclone ALH 3000 workstation ... diagnostic applications, from Genomic and Proteomic Sample ... Assays. The modular design of the ... options and accessories to perfectly meet the ...
... The Sciclone inL10 Workstation from Caliper represents ... offering for the first time the ability ... automatically react to changing conditions. In ... in viscosity due to changes in temperature, ...
ID clarifier: non-treated with lid...
... Workstation fully automates pharmaceutical sample preparation ... sample transfer, mixing and dilutions. Capabilities ... detection. The Prelude performs these functions ... Part 11. The Prelude performs ...
Biology Products: